Expectations and Concerns towards the Up-Coming New Long-Acting Products - Results of a Survey among Haemophilia Patients in Switzerland

Sylvia von Mackensen1, Lino Hostettler2, Jörg Krucker2 & Manuela Alvisseti3,4
1. Institute of Medical Psychology, University Medical Centre, Hamburg, Germany
2. Swiss Hemophilia Society (SHG), Altstätten, Switzerland
3. University Children’s Hospital Zürich, Zürich Switzerland
4. Swiss Hemophilia Network

Introduction

Most haemophilia patients in Western Europe nowadays have the opportunity to receive regular prophylaxis [1] and can have normal lives due to the sufficient availability and funding of plasmatic and recombinant factor concentrates (FC) [2,3]. In patients with severe haemophilia A or B, prophylaxis includes injections of FVIII every other day or three times a week or FIX twice a week, respectively. Poor adherence to prophylaxis may increase the risk of joint bleeds and arthropathy [4,5]. New long acting FC will be launched in the next years and are expected to improve patients’ quality of life [6,7]. Little is known about patients’ perspectives on the use of FC with extended half-life (EHL) [8] and their willingness to switch to these products.

Aim

In order to adapt haemophilia treatment to real patients’ needs, the Swiss patient organisation (SHG) and the Swiss Haemophilia Network (SHN) have conducted a survey to better understand:
• What patients know already about the new FC with EHL
• Which are the expectations, needs and concerns of patients towards these EHL concentrates
• To what extent patients with haemophilia would switch to these new products depending on the half-life.

Study Design & Methods

Survey
• Systematic postal survey among haemophilia A or B patients regarding the new EHL products was sent in January 2016 to all haemophilia A and B patients registered at the SHG.
• In addition haemophilia treatment centres from the SHN sent the survey to their haemophilia patients not registered at the SHG.
• Responses were collected between January and March 2016.

Statistical analyses

All statistical analyses were conducted using the SPSS program version 24 (SPSS Inc., Chicago, IL, USA). Descriptive data are shown as frequency distribution in percent or as means ± standard division SD, median and range.

Results

Willingness to Switch to New Factor Concentrates

<table>
<thead>
<tr>
<th>Patients</th>
<th>Parents</th>
</tr>
</thead>
<tbody>
<tr>
<td>37</td>
<td>61</td>
</tr>
<tr>
<td>61</td>
<td>61</td>
</tr>
<tr>
<td>16</td>
<td>4</td>
</tr>
<tr>
<td>1.7</td>
<td>0</td>
</tr>
</tbody>
</table>

SHG/SHN Survey

• From the respondents, 72.6% were patients, 21% mothers, 5.5% fathers and 2 parents completed the questionnaire together.
• The majority of patients had haemophilia A (85.4%), were severely affected (57.8%), received on-demand treatment (48.1%) and used recombinant FC (65.2%). 14.9% had a history of inhibitors.
• Most of the patients and parents did not know the correct half-life of their actual FC (FVIII: 36.5%, FIX: 80.9%).
• Only 4.3% were unsatisfied with their actual FC; mainly with packaging & device, difficult manageability of FC and short half-life.
• For an adequate decision to switch, patients require the following information: half-life (84.2%), possible side effects (75.1%) and efficacy (69.4%).
• The majority wanted to be informed by their haemophilia centre at the start of treatment (70.9%), bulletin/newsletter of SHG (61.5%) and information letter HTC/SHG (47.9%).

Summary & Conclusions

• In this representative survey, Swiss patients and parents of children with haemophilia reported to be satisfied with their actual FC. Nevertheless, unsatisfactory aspects of their actual FC are packaging & device, difficult manageability of factor concentrate and short half-life.
• The majority had no idea about the half-life of their actual FC.
• Concerning the new FC with EHL more information about half-life, possible side-effects and efficacy was desired.
• A switch to FC with EHL would be considered if the prolongation of the half-life is at least twice as long as the actual FC.
• These survey data provide conclusive answers from a highly representative cohort of Swiss haemophilia patients on the real needs regarding the up-coming FC with EHL.
• These findings will help patient associations and physicians to better inform patients about the new up-coming products taking patients needs into consideration.

References


Disclosures: SVM received a honorarium for the work related to the construction of the questionnaire and the analysis of the survey data from SOBI. The SHG received financial support for printing and shipment of questionnaires from SOBI.